Male hypogonadism, characterized by testosterone deficiency, is a relatively common condition in aging males (>40 years old), and the incidence increases with age. In particular, male hypogonadism is frequently associated with age-related comorbidities such as obesity, muscle weakness, osteoporosis, etc., which deteriorates the quality of life in aging males. We need larger and long-term studies to better clarify aging-related male hypogonadism from clinical or epidemiological perspectives.
Exogenous testosterone replacement therapy is the most widely used treatment for male hypogonadism, but it can induce a series of adverse effects, such as stroke, infertility, heart attack, and prostate tumorigenesis. Thus, we need to explore new promising approaches for testosterone supplementation.
Leydig cells (LCs) located in the testicular interstitium, are the primary source of testosterone. Age-related male hypogonadism is associated with both the loss of LCs and reduced ability to produce testosterone in aging males. Since then, the mechanisms underlying the aging phenotypes of LCs remain to be further elucidated.
This Research Topic aims to reveal the latest advances in aging-related male hypogonadism from clinical or epidemiological perspectives, explore new approaches for testosterone supplementation, and investigate the underlying mechanisms of Leydig cell aging, so as to further understand aging-related male hypogonadism and expand pertinent treatments.
We welcome Original Research, Systematic Reviews, Reviews, and Clinical Trial papers on the following sub-topics, including but not limited to:
• Recent advances in clinical and epidemiological studies of aging-related male hypogonadism
• New approaches for testosterone supplementation
• Underlying mechanisms of Leydig cell aging
Male hypogonadism, characterized by testosterone deficiency, is a relatively common condition in aging males (>40 years old), and the incidence increases with age. In particular, male hypogonadism is frequently associated with age-related comorbidities such as obesity, muscle weakness, osteoporosis, etc., which deteriorates the quality of life in aging males. We need larger and long-term studies to better clarify aging-related male hypogonadism from clinical or epidemiological perspectives.
Exogenous testosterone replacement therapy is the most widely used treatment for male hypogonadism, but it can induce a series of adverse effects, such as stroke, infertility, heart attack, and prostate tumorigenesis. Thus, we need to explore new promising approaches for testosterone supplementation.
Leydig cells (LCs) located in the testicular interstitium, are the primary source of testosterone. Age-related male hypogonadism is associated with both the loss of LCs and reduced ability to produce testosterone in aging males. Since then, the mechanisms underlying the aging phenotypes of LCs remain to be further elucidated.
This Research Topic aims to reveal the latest advances in aging-related male hypogonadism from clinical or epidemiological perspectives, explore new approaches for testosterone supplementation, and investigate the underlying mechanisms of Leydig cell aging, so as to further understand aging-related male hypogonadism and expand pertinent treatments.
We welcome Original Research, Systematic Reviews, Reviews, and Clinical Trial papers on the following sub-topics, including but not limited to:
• Recent advances in clinical and epidemiological studies of aging-related male hypogonadism
• New approaches for testosterone supplementation
• Underlying mechanisms of Leydig cell aging